CA2249733A1 - Inhibiteurs de l'integrine spirocycle - Google Patents

Inhibiteurs de l'integrine spirocycle Download PDF

Info

Publication number
CA2249733A1
CA2249733A1 CA002249733A CA2249733A CA2249733A1 CA 2249733 A1 CA2249733 A1 CA 2249733A1 CA 002249733 A CA002249733 A CA 002249733A CA 2249733 A CA2249733 A CA 2249733A CA 2249733 A1 CA2249733 A1 CA 2249733A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
aminomethyl
oxa
carbonylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002249733A
Other languages
English (en)
Inventor
Joanne Marie Smallheer
Prabhakar Kondaji Jadhav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/816,580 external-priority patent/US5760029A/en
Application filed by Individual filed Critical Individual
Publication of CA2249733A1 publication Critical patent/CA2249733A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne de nouveaux hétérocycles, comprenant l'acide (S)-2-phénylsulfonylamino-3[8-(2-pirydinilaminométhyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionique, qui sont utiles en tant qu'antagonistes de l'intégrine .alpha.¿v?.beta.¿3? et les récepteurs apparentés de protéines adhérant à la surface de cellules, l'invention concernant également des compositions pharmaceutiques contenant ces composés, des procédés de préparation de ces composés, ainsi que des méthodes d'utilisation de ces composés, seuls ou combinés à d'autres agents thérapeutiques pour empêcher l'adhésion cellulaire, le traitement de troubles angiogéniques, l'inflammation, la dégradation osseuse, les métastases de cancer, la rétinopathie diabétique, la thrombose, la resténose, la dégénération maculaire et d'autres états pathologiques induits par l'adhésion cellulaire et/ou la migration cellulaire et/ou l'angiogenèse.
CA002249733A 1996-03-15 1997-03-17 Inhibiteurs de l'integrine spirocycle Abandoned CA2249733A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1353996P 1996-03-15 1996-03-15
US60/013,539 1996-03-15
US64689696A 1996-05-08 1996-05-08
US08/646,896 1996-05-08
US08/816,580 US5760029A (en) 1996-03-15 1997-03-14 Spirocycle integrin inhibitors
US08/816,580 1997-03-14

Publications (1)

Publication Number Publication Date
CA2249733A1 true CA2249733A1 (fr) 1997-09-18

Family

ID=27359885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249733A Abandoned CA2249733A1 (fr) 1996-03-15 1997-03-17 Inhibiteurs de l'integrine spirocycle

Country Status (5)

Country Link
EP (1) EP0888344A1 (fr)
JP (1) JP2001527513A (fr)
AU (1) AU2421797A (fr)
CA (1) CA2249733A1 (fr)
WO (1) WO1997033887A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043962A1 (fr) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Promedicaments heterocycliques inhibiteurs d'integrine
ATE542797T1 (de) 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten
CA2328414C (fr) * 1998-05-08 2014-04-15 The Regents Of The University Of California Procedes de detection et d'inhibition de l'angiogenese
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6586187B1 (en) 1999-04-14 2003-07-01 Wyeth Methods for solid phase combinatorial synthesis of integrin inhibitors
DE19921101A1 (de) * 1999-05-03 2000-11-16 Schering Ag Neue spirocyclische Verbindungen, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung hyperproliferativer Erkrankungen
EP1198231A1 (fr) 1999-07-21 2002-04-24 American Home Products Corporation Antagonistes bicycliques selectifs contre l'integrine(alpha)v (beta)3
AU6316900A (en) 1999-08-05 2001-03-05 Meiji Seika Kaisha Ltd. Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
KR20070009637A (ko) 2004-03-24 2007-01-18 피디엘 바이오파르마 인코포레이티드 암 세포 증식을 억제하는 항α5β1 항체의 용도
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP1739078A1 (fr) 2005-05-30 2007-01-03 Jerini AG Antagonistes du recepteur C5a
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
JP6480653B2 (ja) * 2013-09-26 2019-03-13 株式会社トーキン 導電性高分子溶液
SI3262028T1 (sl) 2014-12-17 2022-02-28 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646966B2 (en) * 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
DE69411584T2 (de) * 1993-11-24 1998-12-17 The Du Pont Merck Pharmaceutical Co., Wilmington, Del. Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten
BR9408137A (pt) * 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU2421797A (en) 1997-10-01
JP2001527513A (ja) 2001-12-25
EP0888344A1 (fr) 1999-01-07
WO1997033887A1 (fr) 1997-09-18

Similar Documents

Publication Publication Date Title
US5760029A (en) Spirocycle integrin inhibitors
CA2249733A1 (fr) Inhibiteurs de l'integrine spirocycle
US6153628A (en) 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as αv β3 antagonists
TW454007B (en) Novel isoxazoline and isozazole fibrinogen receptor antagonists
US6130231A (en) Integrin receptor antagonists
EP0730590B1 (fr) antagonistes de recepteur de fibrinogene, a base d'isoxazoline et d'isoxazole
US5710159A (en) Integrin receptor antagonists
AU5876296A (en) Isoxazoline and isoxazole derivatives as integrin receptor antagonists
WO1995018111A1 (fr) Composes contenant des terminaisons basiques et acides utiles en tant qu'antagonistes des recepteurs de fibrinogene
US20020082253A1 (en) Novel isoxazoline fibrinogen receptor antagonists
HK1023118A (en) Novel isoxazoline and isoxazole fibrinogen receptor antagonists
HRP960234A2 (en) Novel integrin receptor antagonists
MXPA00005155A (en) 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS&agr;v

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead